EANS-News: SYGNIS Pharma AG / SYGNIS announces three months results of fiscal year 2012/2013

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

3-month report

Heidelberg (euro adhoc) - SYGNIS announces three months results of
fiscal year 2012/2013

Heidelberg, August 14, 2012 - SYGNIS Pharma AG (Frankfurt:
LIOK; ISIN DE000A1E9B74; Prime Standard) today reports its
financial results for the first quarter of the fiscal year 2012/2013
ended June 30, 2012.

Financials

- The net loss in the first quarter was EUR-1.2 million (EUR-1.3 million Q1
2011/2012).
- Total operating expenses for the first three months were down at
EUR 1.3 million (EUR2.2 million first quarter 2011/2012).
- Cash including marketable securities amounted to EUR3.0 million as of June
30, 2012 (EUR4.8 million June 30, 2011).

Operational summary

- The focus of the business operations of SYGNIS during the first quarter
was on the preparation of the planned business combination of GENETRIX'
subsidiary X-Pol Biotech and SYGNIS. On 18 July 2012, SYGNIS and GENETRIX
have signed a binding Term Sheet under which the companies propose to
combine X-Pol Biotech - a company focussed on DNA sequencing - and SYGNIS.
Furthermore SYGNIS has signed ahead of schedule a prolongation of the
standby equity distribution agreement (SEDA) with YA Global Master SPV LTD
on 31 July 2012. The binding Term Sheet and the prolongation of SEDA are
subject to an exemption granted by BaFin (Bundesanstalt für
Finanzdienstleistungsaufsicht) from the obligations pursuant to Section 35
of the German Takeover Act (Wertpapiererwerbs- und Übernahmegesetz), in
particular to submit a mandatory tender offer to the existing shareholders
of SYGNIS.
- The operating expenses and the liquidity outflow during the first quarter
were within the expectations of the Company.
- In the KIBRA project further milestones were reached. Initial examinations
with regard to therapeutic peptides are very promising and the development
of a peptide-based medicine represents another approach to treating
dementia.
- The discussions with potential partners for KIBRA were intensified.

Outlook

- For the upcoming months emphasis is being placed on securing sufficient
funding and the further implementation of the strategic realignment
through the proposed merger with X-Pol Biotech. With this merger and the
marketing of existing products and technologies, SYGNIS expects to
generate initial revenues.
- For the KIBRA project SYGNIS is looking for a pharma partner. The Company
has therefore started a systematic partnering process and is in ongoing
discussions with potential partners for the project. However, should the
Company not succeed in winning a partner for KIBRA, the management will
have to reconsider the future of this project.
- The Company's available financial assets as of 30 June 2012 secure the
liquidity of SYGNIS until approximately March 2013. This estimation does
not include revenues that may result from potential research co-operations
for the KIBRA project. To further finance its business activities, the
Company will have to rely on further funding from March 2013 on.

|Key financial figures for the first quarter of fiscal year |
|2012/2013 ended June 30, 2012 and corresponding figures (IFRS) |
|Numbers in million euros |Q1 2012/2013 |Q1 2011/2012 |
|Revenues |0.1 |0.0 |
|Total expenses |1.3 |2.2 |
|EBIT |-1.3 |-2.1 |
|Net results for the period |-1.2 |-1.3 |
|Intangible assets |2.2 |20.6 |
|Liquidity at end of quarter |3.0 |4.8 |
|Equity |4.6 |15.6 |
|(equity ratio in %) |(65) |(52) |
|Long-term financial liabilities |0.0 |8.0 |
|Operating Cash Flow |-1.3 |-2.0 |

The report on the first quarter which ended on June 30, 2012 is available at
the SYGNIS webpage at www.sygnis.de.

For further information please contact:

|
Peter Willinger

|Chief Financial Officer
|
|SYGNIS Pharma AG
|
|Tel.: +49 6221 454 836
|
|E-mail: peter.willinger@sygnis.de
|

About SYGNIS Pharma
SYGNIS Pharma AG (Heidelberg, Germany) is currently a specialty drug
development company, focusing on innovative treatments for underserved human
diseases. Early in 2012 the company decided to discontinue its Phase II lead
program AX200 in stroke. While the company continued research activities in the
field of cognitive disorders, it started at the same time a systematic M&A
process, to add new operational assets and activities to SYGNIS Pharma AG.
SYGNIS Pharma AG is listed in the Prime Standard of the Frankfurt Stock

Exchange under the ticker: LIOK; and ISIN: DE000A1E9B74.

### Disclaimer Some statements included in this press release,
relating neither to proven financial results nor other historical
data, should be viewed as forward- looking, i.e. not definite.
Such statements are mainly predictions of future results, trends,
plans or goals. These statements should not be considered to be
total guarantees since given their very nature they are subject to
known and unknown risks and imponderability and can be affected by
other factors as a consequence of which the actual results, plans
and goals of SYGNIS Pharma AG may deviate greatly from the
established conclusions or implied predictions contained in such
statements. SYGNIS does not undertake to publicly update or revise
these statements in the light of new information or future results
or for any other reason. ###

Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1E9B74
indexes: CDAX, Prime All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
Stuttgart, regulated dealing/prime standard: Frankfurt
language: English